Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Jul 18, 2021 1:01pm
202 Views
Post# 33566891

RE:RE:RE:RE:RE:Landenberg Thalman webcast

RE:RE:RE:RE:RE:Landenberg Thalman webcast
Understandable and I appreciate your candor and can appreciate where you are coming from.
what  I do find difficult is that they are not finding time to return shareholders emails or calls and at the q &A in a previous presentation it appeared that the questions were planted and limited to 2 questions. I posed some questions about institional support and also about the analysts following the stock and as to why the companies that they write about are not supported by their own institutions and my questions were simple and ignored and also they would not respond to my email in regards to the same question....it was not too much to ask and I was very polite but am definately getting more frustrated over time. I know the stock has done well overall in the last 3 years if you timed it right but for any longtierm holders, well that is kinda a different story as the stock had traded as high as about 60 dollars around 10 years ago if we take in the account of the consolidation so when now trading around 3 dollars , well you kind of get my drift. want them to succed for sure but maybe some more insight and better guidance and some of them showing support by maybe buying some more shares might help with shareholder confidence.
<< Previous
Bullboard Posts
Next >>